改进共翻译分离多聚蛋白的2A肽非临床博士研究员(阿斯利康资助)
AstraZeneca funded Non-clinical PhD Studentship (Fixed Term) in Improved 2A Peptides for Co-translational Separation of a Polyprotein
原帖优先:申请材料、截止时间与资格以原帖和学校官方说明为准。
AI 中文速览
- 研究内容
- 该项目聚焦于操纵肽键跳跃序列以改进蛋白质工程,研究并优化新型2A序列以用于生物技术应用(例如细胞疗法)。学生将研究2A肽介导的多聚蛋白共翻译分离机制,解决核糖体脱落、暂停/停滞及分离失败等问题。
- 申请条件
- 原文未说明具体学位或专业背景门槛,详情请点击申请按钮查看。
- 待遇
- 提供为期4年的博士奖学金,起薪为每年23,805英镑,起始日期为2027年10月1日。
- 申请方式
- 请点击原文上方的“Apply”按钮查看详细申请流程并提交申请,截止日期为2026年11月30日。
由 gemini-2.5-flash-lite 生成,博士岗判定置信度 100%。
岗位信息
- 截止
- (Europe/London) 剩 7 天
- 学科
- 生物化学、遗传与分子生物学
- 合同类型
- 雇佣合同
- 原文薪资
- GBP 23,805 / 年(税前)
- 税后月薪(估)
- ¥15,000;房租后 ¥6,700
- 估算假设
- 单身、无子女、雇佣合同的粗略估算,以学校 offer 为准;扣除率 18%;汇率日期 2026-10-01
- 原帖发布
- 本站收录
- 内容更新
- 原帖导师候选(待核验)
- Prof. Andrew Firth, Dr Giovanni Ciotta
- 来源
- jobs.ac.uk(英国博士项目及学术招聘) · 最近核对 2026-11-22
- 详情核验
判定依据(原文摘录)
- 这是一项4年制的博士生培养机会
Applications are invited for a 4-year PhD studentship starting on 1 October 2027
- 项目由剑桥大学和阿斯利康联合资助与指导
based in the Department of Pathology, University of Cambridge, and the AstraZeneca Discovery Centre at Cambridge. The student will be working on a collaborative project jointly supervised by Prof. Andrew Firth at the University of Cambridge and Dr Giovanni Ciotta at AstraZeneca
原文
Applications are invited for a 4-year PhD studentship starting on 1 October 2027 and based in the Department of Pathology, University of Cambridge, and the AstraZeneca Discovery Centre at Cambridge. The student will be working on a collaborative project jointly supervised by Prof. Andrew Firth at the University of Cambridge and Dr Giovanni Ciotta at AstraZeneca and will have the opportunity to work across the two sites. The project focuses on manipulating peptide-bond skipping sequences to aid protein engineering.
2A peptides mediate co-translational separation of a polyprotein via a mechanism known as "ribosome skipping" or "StopGo". These ~20 amino acid peptides adopt an unusual conformation within the translating ribosome that prevents peptide bond formation at a specific site but instead promotes release of the nascent peptide followed by continuation of translation. These sequences have proved to be exceptionally useful in biotechnology because they allow the introduction of all components of a pathway or multi-subunit complex in a single step, with stable stoichiometric co-expression from a single promoter. However, 2A peptides have some caveats - including ribosome drop-off, ribosome pausing/stalling, and some amount of separation failure - which constrain their functional utility. We have identified new classes of 2A sequences, some of which have improved properties compared to traditional 2A peptides. This PhD project will contribute to our work investigating these new 2A sequences and optimising them for biotechnological applications.
The UCam team has expertise in molecular biology including ribosome profiling, ribosome structure and function, cell biology, cryo-electron microscopy, and bioinformatics. The AZ team has expertise in cell therapy, CRISPR/Cas9 technologies, and viral vectors. The PhD project will focus on molecular biology techniques but there will also be opportunity for bioinformatic skill development and there may be scope to obtain structural biology experience. At the AstraZeneca site, the student will focus on implementing optimised sequences in specific biotechnological applications, e.g. in cell therapy.
For full details and application process please click the 'Apply' button above. From £23,805 per annum